Evidence map›Paper›PMID 28100618›Full record

ArticleJournal of virology2017

Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses.

Jérémie Prévost, Daria Zoubchenok, Jonathan Richard, Maxime Veillette, Beatriz Pacheco, Mathieu Coutu, Nathalie Brassard, Matthew S Parsons, Kiat Ruxrungtham, Torsak Bunupuradah and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 62 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 4 countries.

Jérémie PrévostCentre de Recherche du CHUM, Montreal, QC, Canada.
Daria ZoubchenokCentre de Recherche du CHUM, Montreal, QC, Canada.
Jonathan RichardCentre de Recherche du CHUM, Montreal, QC, Canada.
Maxime VeilletteCentre de Recherche du CHUM, Montreal, QC, Canada.
Beatriz PachecoCentre de Recherche du CHUM, Montreal, QC, Canada.
Mathieu CoutuCentre de Recherche du CHUM, Montreal, QC, Canada.
Nathalie BrassardCentre de Recherche du CHUM, Montreal, QC, Canada.
Matthew S ParsonsDepartment of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Kiat RuxrungthamHIVNAT, Thai Red Cross AIDS Research Center, Bangkok, Thailand.
Torsak BunupuradahHIVNAT, Thai Red Cross AIDS Research Center, Bangkok, Thailand.
Sodsai TovanabutraU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Kwan-Ki HwangDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Mattia BonsignoriDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Joseph SodroskiDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, and Department of Microbiology and Immunobiology, Division of AIDS, Harvard Medical School, Boston, Massachusetts, USA.
Daniel E KaufmannCentre de Recherche du CHUM, Montreal, QC, Canada.
George M ShawDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Agnès L ChenineU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Andrés FinziCentre de Recherche du CHUM, Montreal, QC, Canada andres.finzi@umontreal.ca.
Centre Hospitalier de l’Université de Montréal · CADuke Medical Center · USHIV Netherlands Australia Thailand Research Collaboration · THDana-Farber Cancer Institute · USHenry M. Jackson Foundation · USUniversité de Montréal · CAUniversity of Melbourne · AUUniversity of Pennsylvania · USWalter Reed Army Institute of Research · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2012 to 2018
$204.7M
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7M
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01GM056550 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ABRAMS, CAMERON F · 1997 to 2018
$31.2M
Conformational Landscape of the HIV-1 Envelope GlycoproteinsR01AI124982 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2016 to 2025
$6.7M
Immunoregulatory networks and HIV pathogenesisR01HL092565 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KAUFMANN, DANIEL E · 2007 to 2015
$3.4M
bNAb induction by antigenically diverse V1V2 lineage specific SHIVs and SOSIPsR01AI131331 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2017 to 2020
$3.2M
Structural Targeting of Potentially Protective gp120 Epitopes in the C1/C2 RegionR01AI116274 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PAZGIER, MARZENA ELZBIETA · 2016 to 2019
$1.5M
Reducing viral reservoirs by opening HIV-1 Env to antibody attackR21AI129017 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2017 to 2018
$459k
CIHR 352417CIHR MOP93770NHLBI NIH HHS R01 HL092565NIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI116274NIAID NIH HHS R01 AI124982NIAID NIH HHS R01 AI131331NIAID NIH HHS R21 AI129017NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1 AI100663NIGMS NIH HHS P01 GM056550
6 · The paper itself

Abstract

HIV-1-infected cells presenting envelope glycoproteins (Env) in the CD4-bound conformation on their surface are preferentially targeted by antibody-dependent cellular-mediated cytotoxicity (ADCC). HIV-1 has evolved sophisticated mechanisms to avoid the exposure of Env ADCC epitopes by downregulating CD4 and by limiting the overall amount of Env on the cell surface. In HIV-1, substitution of large residues such as histidine or tryptophan for serine 375 (S375H/W) in the gp120 Phe 43 cavity, where Phe 43 of CD4 contacts gp120, results in the spontaneous sampling of an Env conformation closer to the CD4-bound state. While residue S375 is well conserved in the majority of group M HIV-1 isolates, CRF01_AE strains have a naturally occurring histidine at this position (H375). Interestingly, CRF01_AE is the predominant circulating strain in Thailand, where the RV144 trial took place. In this trial, which resulted in a modest degree of protection, ADCC responses were identified as being part of the correlate of protection. Here we investigate the influence of the Phe 43 cavity on ADCC responses. Filling this cavity with a histidine or tryptophan residue in Env with a natural serine residue at this position (S375H/W) increased the susceptibility of HIV-1-infected cells to ADCC. Conversely, the replacement of His 375 by a serine residue (H375S) within HIV-1 CRF01_AE decreased the efficiency of the ADCC response. Our results raise the intriguing possibility that the presence of His 375 in the circulating strain where the RV144 trial was held contributed to the observed vaccine efficacy.

Indexed as

Antibody-Dependent Cell CytotoxicityAIDS VaccinesAmino Acid MotifsAmino Acid SequenceBinding SitesConsensus SequenceHEK293 CellsHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHumansProtein BindingAIDS Vaccinesgp120 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120ADCCEnvgp120HIV-1Phe 43 cavityRV144

Identifiers

PMID28100618
PMCPMC5355605
OpenAlexW2577720010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.